Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study

被引:21
|
作者
Spadea, A. [1 ]
Unim, B. [2 ]
Colamesta, V. [2 ]
Meneghini, A. [1 ]
D'Amici, A. M. [1 ]
Giudiceandrea, B. [1 ]
La Torre, G. [2 ,3 ]
机构
[1] RM A Local Hlth Unit, Rome, Italy
[2] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy
[3] Eleonora Lorillard Spencer Cenci Fdn, Rome, Italy
关键词
TIV; MF59; ATIV; Elderly; Influenza; Hospitalization; ANTIBODY-RESPONSE; HEALTH; HOSPITALIZATION; COMMUNITY; MORTALITY; CHILDREN; SAFETY;
D O I
10.1016/j.vaccine.2014.07.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Influenza illness is an important public health problem and annual vaccination is globally recommended for high risk populations. Objective: The aim was to evaluate and compare the effectiveness of influenza vaccines in reducing hospitalizations for influenza or pneumonia during two influenza seasons in the elderly. Methods: A case-control study was performed, using administrative database of the Local Health Unit Roma-A (LHU RM-A). The included subjects were at least 65 years old and residing in one of the four districts of the LHU. The cases were hospitalized for influenza or pneumonia during influenza season in the years 2010-2011 and 2011-2012. The controls were hospitalized in the same period, but not for influenza or pneumonia. The subjects were immunized with the trivalent inactivated influenza vaccine (TIV) in the first influenza season (2010-2011) and with the adjuvanted influenza vaccine MF59 (ATIV) in the second season (2011-2012). Results: A total of 269 cases and 1247 controls were included for the 2010-2011 influenza season, and 365 cases and 1227 controls were selected for the 2011-2012 season. Up to 63.6% cases and 53.5% controls in the 2010-2011 season and 78.6% of cases and 64.1% of controls in the 2011-2012 season have not been vaccinated. Female gender and high educational level were protective factors for hospitalization. Subjects over 75 years were at high risk of hospitalization compared to 65-74 years olds. Influenza vaccination reduced significantly hospitalization in both seasons. In subjects with 65-74 years TIV was more effective than ATIV; vice versa for those over 75 years old. Discussion and conclusion: TIV and ATIV reduce hospitalization for influenza or pneumonia with a variable degree of protection in different age groups. In particular, ATIV is more effective in individuals over 75 years old. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5290 / 5294
页数:5
相关论文
共 50 条
  • [41] A case-control study on risk factors of domestic accidents in an elderly population
    Camilloni, Laura
    Farchi, Sara
    Rossi, Paolo Giorgi
    Chini, Francesco
    Di Giorgio, Maurizio
    Molino, Nunzio
    Iannone, Amalia
    Borgia, Piero
    Guasticchi, Gabriella
    INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION, 2011, 18 (04) : 269 - 276
  • [42] Association of Influenza Vaccination and Reduced Risk of Stroke Hospitalization among the Elderly: A Population-Based Case-Control Study
    Lin, Hui-Chen
    Chiu, Hui-Fen
    Ho, Shu-Chen
    Yang, Chun-Yuh
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2014, 11 (04): : 3639 - 3649
  • [43] Immunogenicity of the Trivalent Inactivated Influenza Vaccine in Young Children Less than 4 Years of Age, with a Focus on Age and Baseline Antibodies
    Mugitani, Ayumi
    Ito, Kazuya
    Irie, Shin
    Eto, Takashi
    Ishibashi, Motoki
    Ohfuji, Satoko
    Fukushima, Wakaba
    Maeda, Akiko
    Hirota, Yoshio
    CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (09) : 1253 - 1260
  • [44] Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study
    Vasileiou, Eleftheria
    Sheikh, Aziz
    Butler, Chris C.
    Robertson, Chris
    Kavanagh, Kimberley
    Englishby, Tanya
    Lone, Nazir, I
    von Wissmann, Beatrix
    McMenamin, Jim
    Ritchie, Lewis D.
    Schwarze, Jurgen
    Gunson, Rory
    Simpson, Colin R.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (07) : E94 - E104
  • [45] Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)
    Pott, Henrique
    Andrew, Melissa K.
    Shaffelburg, Zachary
    Nichols, Michaela K.
    Ye, Lingyun
    ElSherif, May
    Hatchette, Todd F.
    LeBlanc, Jason
    Ambrose, Ardith
    Boivin, Guy
    Bowie, William
    Johnstone, Jennie
    Katz, Kevin
    Lagace-Wiens, Phillipe
    Loeb, Mark
    McCarthy, Anne
    McGeer, Allison
    Poirier, Andre
    Powis, Jeff
    Richardson, David
    Semret, Makeda
    Smith, Stephanie
    Smyth, Daniel
    Stiver, Grant
    Trottier, Sylvie
    Valiquette, Louis
    Webster, Duncan
    McNeil, Shelly A.
    VACCINE, 2023, 41 (42) : 6359 - 6365
  • [46] Are healthcare workers more likely than the general population to consult in primary care for an influenza-like illness? Results from a case-control study
    Peytremann, Arnaud
    Senn, Nicolas
    Mueller, Yolanda
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2020, 14 (05) : 524 - 529
  • [47] Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly
    B. R. Ruf
    K. Colberg
    M. Frick
    A. Preusche
    Infection, 2004, 32 : 191 - 198
  • [48] Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study
    Simpson, Colin R.
    Lone, Nazir, I
    Kavanagh, Kim
    Englishby, Tanya
    Robertson, Chris
    McMenamin, Jim
    von Wissman, Beatrix
    Vasileiou, Eleftheria
    Butler, Christopher C.
    Ritchie, Lewis D.
    Gunson, Rory
    Schwarze, Jurgen
    Sheikh, Aziz
    HEALTH TECHNOLOGY ASSESSMENT, 2020, 24 (67) : 1 - +
  • [49] Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®) An open label, uncontrolled study
    Vinnemeier, Christof David
    Fischer-Herr, Johanna
    Meyer, Seetha
    Liebig, Katja
    Theess, Wiebke
    Burchard, Gerd-Dieter
    Cramer, Jakob P.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (02) : 441 - 448
  • [50] Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
    Chu, Daniel Wai-Sing
    Hwang, Shinn-Jang
    Lim, Fong Seng
    Oh, Helen May Lin
    Thongcharoen, Prasert
    Yang, Pan-Chyr
    Bock, Hans L.
    Drame, Mamadou
    Gillard, Paul
    Hutagalung, Yanee
    Tang, Haiwen
    Teoh, Yee Leong
    Ballou, Ripley W.
    VACCINE, 2009, 27 (52) : 7428 - 7435